Compare · GLP-1 agonist
Ecnoglutide vs Semaglutide
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Ecnoglutide | Semaglutide | |
|---|---|---|
| Evidence | 7/10 | 10/10 |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | A long-acting, cAMP-biased GLP-1 receptor agonist approved in China for type 2 diabetes and weight management, with genuine peer-reviewed Phase 3 data that is still confined to Chinese populations and not FDA-approved. | A GLP-1 drug with strong RCT evidence for weight loss, glucose control, and cutting cardiovascular events in high-risk patients. |
| Full profile → | Full profile → |
Ecnoglutide
Ecnoglutide (its development name is XW003) is an injectable drug for type 2 diabetes and weight loss. It belongs to the same broad family of medicines as semaglutide — the GLP-1 receptor agonists (drugs that copy a natural gut hormone to lower blood sugar and curb appetite). Two things make it…
Semaglutide
Semaglutide is one of the most heavily studied metabolic drugs of the past decade. Unlike most of the compounds we cover here, the human evidence is large, long-running, and consistent. So the honest job is simple: lay out where it holds up and where it doesn't.